使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good afternoon participants. Welcome to the third quarter earnings release conference call. All lines are going to be on listen-only until the question and answer portion of today's program and at the request of our call leader, this conference is being recorded. Any objections, you must disconnect at this time. I would now like to turn the call over to our Vice President of Finance, Treasurer, and Corporate Controller of Intuitive Surgical Mr. Ben Gong. Sir, you may begin when ready.
各位與會者,下午好。歡迎參加第三季財報發布電話會議。在今天節目的問答環節開始之前,所有線路將維持僅收聽狀態;並且依照本次會議主持人的要求,本次會議將被錄音。如有任何異議,請您此刻中斷連線。現在我想把電話會議交給直覺外科(Intuitive Surgical)的財務副總裁、財務長兼公司主計長 Ben Gong 先生。先生,您準備好即可開始。
BENJAMIN M. GONG - Intuitive Surgical
BENJAMIN M. GONG - Intuitive Surgical
Good afternoon. Welcome to Intuitive Surgical third quarter conference call. With me today we have Lonnie M. Smith our President & CEO, Susan K. Barnes our Chief Financial Officer, Frederic H. Moll our Co-Founder and Medical Director, Aleks Cukic our Vice President of Business Development and Strategic Planning, and David M. Shah our Vice President of Legal Affairs and Corporate Counsel. Before we begin, I would like to inform you that comments mentioned in today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's Securities and Exchange Commission filings. Investors are cautioned not to place undue reliance on such forward-looking statements. Please note that this conference call will be available for audio replay on our website at www.IntuitiveSurgical.com on the audio archives section under our investor relations page. In addition, today's press release has been posted to our website. Today's format will consist of providing you with highlights of the third quarter as described in our press release announced earlier today followed by a question and answer session. First, Lonnie will present the business highlights of the third quarter; Susan will follow with a review of our third quarter financial results and provide an outlook for the fourth quarter. Next, Fred will describe our most recent clinical and regulatory progress, Aleks will discuss Sales & Marketing, and then Dave will update you regarding intellectual property issues. Finally, we will host a question and answer session. With that, I would like to introduce Lonnie Smith our President & CEO.
各位下午好。歡迎參加直覺外科第三季電話會議。今天與我一同出席的有:我們的總裁暨執行長 Lonnie M. Smith、財務長 Susan K. Barnes、共同創辦人暨醫療總監 Frederic H. Moll、業務發展與策略規劃副總裁 Aleks Cukic,以及法務事務與公司法律顧問副總裁 David M. Shah。在開始之前,我想提醒各位,今天電話會議中提及的評論可能被視為包含前瞻性陳述。由於某些風險與不確定性,實際結果可能與所表達或暗示者有重大差異。這些風險與不確定性已在公司向美國證券交易委員會(SEC)提交的文件中有詳細說明。提醒投資人勿過度依賴此類前瞻性陳述。請注意,本次電話會議的音訊重播將可於我們網站 www.IntuitiveSurgical.com 的投資人關係頁面下之音訊存檔區取得。此外,今天的新聞稿也已張貼於我們的網站。今天的流程將先提供第三季重點摘要(如我們今日稍早發布的新聞稿所述),接著進行問答環節。首先,Lonnie 將介紹第三季的業務重點;接著 Susan 將回顧第三季財務結果並提供第四季展望。之後,Fred 將說明我們最新的臨床與法規進展,Aleks 將討論銷售與行銷,然後 Dave 將就智慧財產權議題向各位更新。最後,我們將進行問答環節。接下來,我想介紹我們的總裁暨執行長 Lonnie Smith。
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
Thank you Ben. I would like to thank each of you who have taken the time to join us for today's conference call. I will begin with a review of the highlights of the third quarter. Financially, we had a solid third quarter revenue and margin results. We shipped 14 da Vinci surgical systems, ended the quarter with a 132 systems installed worldwide, achieved revenue of $17.1 million, up 57% from prior year, grew recurring revenue to $3.9 million, up 135% from prior year, grew gross margin to 51%, up from 47% in Q3 2001. Regarding operating expenses net loss, we recorded total operating expenses of $15.6 million up 42% from prior year, had a net loss of $6.5 million or $0.18 a share and ended the quarter with $48.5 million in cash. We are pleased with our revenue growth and improving gross margins in a seasonally slow third quarter. We continue to see healthy growth in our recurring revenue stream, increased system usage. We are however not happy with our third quarter operating expenses and net loss results. We had higher-than-anticipated expenses this quarter due primarily to the impact of two non-recurring items - first, we made a significant investment during the quarter in our litigation against Computer Motion in Delaware, which included the trial in August. While this is not our preferred type of investment, we believe that defending our intellectual property is very important to the long-term success of our company. Second, during the quarter we incurred significant expenses associated with unauthorized purchases of administrative supplies for which we have no use. A non-management employee circumvented company processes and purchased without proper authorization materials at a highly inflated price that neither fit our needs nor work with the products we are on. We believe that this employee was improperly enticed to do so by an unscrupulous vendor. Our financial review exposed this activity and we have tightened our processes to prevent any future recurrence of this kind of activity. We are pursuing collection of monies from the vendor and from our insurance company to cover our losses from these illegal activities. In the meantime, we have booked a loss in the quarter to cover the full $930,000 incurred. Appropriate law enforcement agencies are investigating this issue and it would inappropriate to comment further at this time. Our cash use was impacted by the timing of the bulk of our systems shipments in September and follows a seasonal pattern similar to that we had experienced in prior years. Operationally, we had an excellent American College of Surgeons meeting in San Francisco. We introduced an additional fourth arm for the da Vinci surgical system. The fourth arm provides enhanced surgical capability, improves operating efficiency, and as a significant step towards solo-surgery for many procedures. Dr. Aston Call of the West Chester Medical Center performed a live broadcast of a gastric bypass procedure to the J&J Ethicon Endo-Surgical booth during the conference as part of our core marketing partnership. The surgery went beautifully with a 20-minute sutured double-layered anastomosis. We won a $4.4 million jury verdict versus Computer Motion in the Delaware Patent Infringement trial. The judge's decision regarding Computer Motion's latch's defense is still pending. We released 2 new energy-based surgical instruments, the Prim Electrocuatery and Bipolar Forceps. These new tools continue to improve the clinical capability of our system. We submitted our Mital Valve 510k with the FDA, summarizing the excellent results of our trial, and expect to obtain clearance for this cardiac indication in the fourth quarter. We reorganized our European operations and named Esco Viscari as a Director of the European Sales & Marketing. Esco brings to us 13 years of proven sales & marketing experience with Guidance and Ventrica and we look forward to the leadership that Esco brings to the European team. Finally, we enjoyed a quarter of continued clinical progress and success. Ultimately, the success of our business is a direct result of the surgical capability and clinical benefits that the da Vinci surgical system delivers to surgeons and to their patients. Fred will give a detailed clinical review later in this call. With that, I will pass the time over to Susan who will discuss our third quarter financial results.
謝謝你,Ben。感謝各位撥冗參加今天的電話會議。我將先回顧第三季的重點摘要。就財務面而言,我們第三季的營收與毛利率表現穩健。我們出貨 14 套達文西(da Vinci)手術系統,季末全球安裝量達 132 套;營收達 1,710 萬美元,較去年同期成長 57%;經常性收入增至 390 萬美元,較去年同期成長 135%;毛利率提升至 51%,高於 2001 年第三季的 47%。關於營業費用與淨損方面,我們記錄的營業費用總額為 1,560 萬美元,較去年同期增加 42%;淨損為 650 萬美元或每股 0.18 美元;季末現金為 4,850 萬美元。我們對於在季節性偏淡的第三季仍能達成營收成長並改善毛利率感到滿意。我們持續看到經常性收入來源的健康成長,以及系統使用量的提升。然而,我們對第三季的營業費用與淨損結果並不滿意。本季費用高於預期,主要是受到兩項一次性事項的影響——第一,我們在本季對於在德拉瓦州與 Computer Motion 的訴訟進行了重大投入,其中包括 8 月的審判。雖然這不是我們偏好的投資類型,但我們相信捍衛智慧財產權對公司長期成功非常重要。第二,本季我們因未經授權採購行政用品而產生了可觀費用,而這些用品對我們並無用途。一名非管理職員工規避公司流程,在未取得適當授權的情況下,以高度膨脹的價格購買了既不符合我們需求、也無法與我們現有產品配合使用的物料。我們相信該員工是受到不肖供應商不當引誘而為之。我們的財務審查揭露了此活動,並已強化流程,以防止未來再次發生此類事件。我們正向該供應商及我們的保險公司追討款項,以彌補這些非法活動造成的損失。同時,我們已在本季認列損失,以涵蓋所發生的 93 萬美元全額支出。相關執法機關正在調查此事,目前不宜進一步評論。我們的現金使用量受到 9 月大部分系統出貨時點的影響,並呈現與往年類似的季節性模式。在營運方面,我們在舊金山舉行的美國外科醫師學會(American College of Surgeons)年會上表現出色。我們為達文西手術系統推出了額外的第四支機械臂。第四支機械臂可提供更強的手術能力、提升手術效率,並且是朝向多項術式「單人手術」邁出的重要一步。West Chester Medical Center 的 Aston Call 醫師在會議期間,作為我們核心行銷合作夥伴關係的一部分,向 J&J Ethicon Endo-Surgical 的展位進行了一場胃繞道手術的現場直播。手術進行得非常順利,完成了 20 分鐘的縫合雙層吻合。我們在德拉瓦州專利侵權審判中,對 Computer Motion 贏得 440 萬美元的陪審團裁決。法官對於 Computer Motion 的 latch's 抗辯之裁定仍在等待中。我們推出了 2 款新的能量型手術器械:Prim 電燒器(Electrocautery)與雙極鉗(Bipolar Forceps)。這些新工具持續提升我們系統的臨床能力。我們已向美國食品藥物管理局(FDA)提交二尖瓣(Mitral Valve)510(k) 申請,彙整了試驗的優異結果,並預期在第四季取得此心臟適應症的核准。我們重整了歐洲營運,並任命 Esco Viscari 擔任歐洲銷售與行銷總監。Esco 擁有在 Guidance 與 Ventrica 累積的 13 年經驗、且具備經驗證明的銷售與行銷實績;我們期待 Esco 為歐洲團隊帶來的領導力。最後,我們很高興本季臨床進展與成功持續推進。歸根結底,我們業務的成功直接來自達文西手術系統為外科醫師及其病患所帶來的手術能力與臨床效益。Fred 將在本次電話會議稍後提供更詳細的臨床回顧。接下來,我把時間交給 Susan,由她說明我們第三季的財務結果。
SUSAN K. BARNES - Intuitive Surgical
SUSAN K. BARNES - Intuitive Surgical
Thank you Lonnie. As Lonnie highlighted, we ended the quarter with strong operating results. We realized $17.1 million of revenue, 57% above last year. We sustained gross margin at 51% exceeding 50% for 2 quarters in a row. We grew recurring revenue to $3.9 million up 135% over the previous year. Operating expenses grew to $15.6 million up 42% from Q3 2001 and we recorded a net loss of $0.18 per share and used $6.9 million in cash. Going into more detail, our third quarter 2002 revenue was $17.1 million up 57% from third quarter 2001 revenue of $10.9 million. We shipped 14 da Vinci surgical systems during the quarter; 13 in the United States and 1 in Europe. The 14 total units shipped were up 4 compared to 10 units shipped during the third quarter of 2001. We now have cumulative placements of 132 systems - 88 in the US, 39 in Europe, and 5 in the rest of the world. Total Q3 2002 revenue by product group was as follow: Systems $13.2 million, Instruments & Accessories $2.5 million, and Service $1.4 million. Recurring revenue was up 135% compared to Q3 2001. Recurring revenue grew to $3.9 million or 23% of total revenue compared to $1.7 million or 15% of revenue in the third quarter of 2001. Our recurring revenue continues to climb each quarter as we place more systems, as our customers perform more robotic procedures. Year-to-date sales totaled $58.9 million up $15.2 million or 43% compared to the first nine months of 2001. Third quarter 2002 gross margins rose to 51% compared to the 47% in the same quarter last year. The improvement in gross margin over the prior year is due to higher sales volume and higher da Vinci surgical systems selling prices. Total operating expenses for the third quarter 2002 was $15.6 million, up $4.6 million or 42% compared to the third quarter of 2001. SG&A expenses were $11.4 million in the third quarter of 2002, up approximately $4.2 million from $7.5 million in the third quarter of 2001. SG&A for he quarter was higher than we had anticipated due to the impact of higher litigation expenses and the write-off of unauthorized purchases that Lonnie described earlier. As previously announced, the Delaware jury did in fact award us $4.4 million in damages. Because post-trial proceedings have not concluded we have not received or accrued any of these funds. We will only record the judgment awarded when and if actual cash is received. And in addition to the non-routine items, SG&A expenses grew over previous periods due to headcount growth in our field sales and support organizations. R&D expense was $3.9 million in the third quarter 2002, up approximately $400,000 from the $3.5 million incurred in the third quarter of last year. The increase versus prior year resulted primarily from headcount growth. We ended the quarter with 278 regular employees, up 6 from the previous quarter end. Total worldwide field employees accounted for 5 of the adds, increasing from 69 to 74 during the quarter. Non-cash deferred compensation and patent amortization expenses represented $300,000 of total operating expenses in Q3 2002 compared to $500,000 in Q3 2001. The balance of unamortized deferred compensation is now down to $300,000 and should be completely amortized early next year. Our balance of unamortized patents is now $2.7 million, which we will amortize at a straight line rate of $200,000 per quarter until it is fully expensed. Intuitive Surgical had $400,000 of other incomes for Q3 2002, compared to $1 million in the third quarter of 2001. The decrease is due to lower cash balances and lower rates of return earned on cash investments. Our net loss for the third quarter 2002 was $6.5 million or $0.18 per share compared to $4.8 million or $0.13 per share in the third quarter of 2001. Basic and diluted shares outstanding for EPS calculations were 36 million shares for the third quarter 2002 compared to 36.1 million for the same period last year. Moving to our balance sheet, we ended the quarter with $48.5 million in cash, down $6.9 million from the previous quarter end. The reduction reflected the company's net loss of $6.3 million and increases in accounts receivable and inventory offset by non-cash expenses and higher current liabilities' balances. Our current day sales outstanding was 100 days up from 71 at the end of Q2. Ending fourth quarter net inventory was $9.9 million up about $2.6 million from previous quarter end, reflecting a buildup to support higher fourth quarter revenue plans. Our outlook for the fourth quarter, we expect fourth quarter revenues to come in between $21 and 25 million on system unit shipments of between 18 and 22 systems. We anticipate Q4 growth margins to increase slightly due to higher sales. Taking into account the non-recurring items that impacted Q3, we expect operating expenses to be down slightly from Q3 levels. We expect the average number of shares outstanding during the fourth quarter 2002 for EPS calculations to be approximately 36.6 million shares. With that, I would like to turn it over to Fred who will provide a summary of our latest clinical progress.
謝謝你,Lonnie。如 Lonnie 所強調的,我們以強勁的營運成果結束本季。我們實現營收 1,710 萬美元,較去年成長 57%。我們將毛利率維持在 51%,連續兩個季度超過 50%。我們將經常性收入提升至 390 萬美元,較前一年成長 135%。營業費用增至 1,560 萬美元,較 2001 年第三季成長 42%;我們錄得每股淨損 0.18 美元,並使用了 690 萬美元現金。進一步說明,2002 年第三季營收為 1,710 萬美元,較 2001 年第三季的 1,090 萬美元成長 57%。本季我們出貨 14 套 da Vinci 手術系統;其中 13 套在美國、1 套在歐洲。本季出貨總數 14 套,較 2001 年第三季出貨 10 套增加 4 套。我們目前累計裝機 132 套系統——美國 88 套、歐洲 39 套、世界其他地區 5 套。2002 年第三季按產品組別的總營收如下:系統 1,320 萬美元、器械與配件 250 萬美元、服務 140 萬美元。經常性收入較 2001 年第三季成長 135%。經常性收入增至 390 萬美元,占總營收 23%;相較之下,2001 年第三季為 170 萬美元,占營收 15%。隨著我們部署更多系統、客戶執行更多機器人手術,我們的經常性收入每季持續攀升。年初至今銷售額合計 5,890 萬美元,較 2001 年前九個月增加 1,520 萬美元(成長 43%)。2002 年第三季毛利率升至 51%,高於去年同期的 47%。毛利率較前一年改善,主要由於銷售量提高以及 da Vinci 手術系統售價較高。2002 年第三季營業費用總額為 1,560 萬美元,較 2001 年第三季增加 460 萬美元(成長 42%)。2002 年第三季 SG&A 費用為 1,140 萬美元,較 2001 年第三季的 750 萬美元增加約 420 萬美元。本季 SG&A 高於我們先前預期,原因是較高的訴訟費用影響,以及 Lonnie 先前所述未經授權採購的沖銷。如先前公告,特拉華州陪審團確實裁定我們獲得 440 萬美元的損害賠償。由於審後程序尚未結束,我們尚未收到或應計入任何該等款項。我們僅會在實際收到現金時(且若收到)才會認列該項判決金額。此外,除上述非常態項目外,SG&A 費用較前期增加,係因我們外勤銷售與支援組織的人員編制成長所致。2002 年第三季研發費用為 390 萬美元,較去年第三季的 350 萬美元增加約 40 萬美元。相較前一年之增加主要源於人員編制成長。本季末我們有 278 名正式員工,較上一季季末增加 6 名。全球外勤員工占新增人數中的 5 名,使本季由 69 名增至 74 名。2002 年第三季,非現金遞延薪酬與專利攤銷費用占營業費用總額 30 萬美元;相較之下,2001 年第三季為 50 萬美元。未攤銷的遞延薪酬餘額目前降至 30 萬美元,預計將於明年初完全攤銷完畢。未攤銷專利餘額目前為 270 萬美元,我們將以每季 20 萬美元的直線法攤銷,直到全數費用化。Intuitive Surgical 在 2002 年第三季的其他收入為 40 萬美元,較 2001 年第三季的 100 萬美元為低。下降原因是現金餘額較低,以及現金投資所獲報酬率較低。2002 年第三季淨損為 650 萬美元或每股 0.18 美元;相較之下,2001 年第三季為 480 萬美元或每股 0.13 美元。用於每股盈餘(EPS)計算的基本及稀釋後流通股數,2002 年第三季為 3,600 萬股,去年同期為 3,610 萬股。接著看資產負債表,本季末我們持有現金 4,850 萬美元,較上一季季末減少 690 萬美元。該減少反映公司淨損 630 萬美元,以及應收帳款與存貨增加;部分由非現金費用與流動負債餘額提高所抵銷。目前的應收帳款周轉天數(DSO)為 100 天,較第二季末的 71 天上升。第四季末存貨淨額為 990 萬美元,較上一季季末增加約 260 萬美元,反映為支援第四季較高營收計畫而進行的備貨。對於第四季展望,我們預期第四季營收介於 2,100 萬至 2,500 萬美元,系統出貨量介於 18 至 22 套。我們預期第四季毛利率將因銷售增加而小幅上升。考量影響第三季的非經常性項目後,我們預期營業費用將較第三季水準略為下降。我們預期 2002 年第四季用於 EPS 計算的平均流通股數約為 3,660 萬股。接下來,我想把時間交給 Fred,由他為我們最新的臨床進展做摘要。
FREDERIC H. MOLL - Intuitive Surgical
FREDERIC H. MOLL - Intuitive Surgical
Thanks Susan. I am pleased to report that during the quarter we have made significant clinical progress in each of our primary surgical markets- urology, general surgery, and cardio thoracic surgery. Regarding the urology market, the da Vinci prostatectomy procedure or DVP as we refer to it had another outstanding quarter with continued growth in a number of procedures being performed as well as the number of institutions performing the surgery. As case numbers grow, there is mounting clinical evidence, which documents the clear benefits of DVP. In the September edition of the Journal of Urology an article was published comparing the clinical results of the DVP versus laparoscopic prostatectomy. While the benefits as compared to traditional open techniques are obvious, this study compared the first 40 cases, learning curve included, performed by Dr. Mani Menon at Henryford Hospital to the combined results of over 600 cases performed by the world's most experienced laparoscopic prostate surgeons Dr. Givelensian and Dr. Bertrand Genive. Average operating times were 274 minutes with the da Vinci compared to 258 for a laparoscopic procedure. However, note that Dr. Menon now further along in his learning curve routinely performs cases in a 120 minutes or 2 hours faster than the most experienced laparoscopists. The patient benefits were also addressed in this study. Average blood loss was only 256 cc with DVP compared to 391 cc with LRP. Also, cancer removal was more complete with DVP, orbit of surgical margins were 17.5% as compared to 25% with LRP. Finally, 80% da Vinci patients went home within 24 hours of surgery compared to 65% using laparoscopic technique. Patient's discharge at 24 hours represents a 2.5- to 3-day reduction in hospital recovery compared to open surgical techniques. In addition to providing an excellent procedure base for the da Vinci system, DVP has opened the door to many other urologic procedures that can improve with the use of robotics. We are experiencing growth in a variety of urologic surgeries such as pyeloplasty and partial nephrectomy. In an article published in the September edition of Urology, the Male Clinic Rochester reported the mean operative times at their institution had been reduced in the procedure of pyeloplasty by the use of da Vinci from 214 minutes to 139 minutes when compared to conventional laparoscopic technique. Additionally, a team of plastic and urologic surgeons from the Cleveland Clinic performed the world's first DVP with bilateral sural nerve grafting. This procedure involves harvesting a cutaneous nerve from the leg and using it to restore the continuity of the nerve bundle that was excised during the prostatectomy. The expectation is that the use of nerve graft may improve potency after prostate removal. Finally, in New York University Medical Center, surgeons have gained experience with the da Vinci in the procedure of partial nephrectomy. A partial nephrectomy is performed when removing a renal tumor that is less than 4 cm in size. This procedure is reconstructive in nature and can be used in lieu of kidney transplantation. With increasing organ shortages, the capability to repair rather than replace diseased kidneys will be extremely valuable. In the cardiac area, we have gained momentum in minimally invasive cavage surgery. Several European institutions are routinely performing beating heart bypass procedures with da Vinci as the primary surgical tool. Recently, Dr. Gearhart van Engraniger performed a live broadcast of a closed-chest endoscopic beating heart bypass procedure in less than 2 hours at a European meeting of Cardiac Surgeons. Domestically, momentum is building in the cardiac arena in anticipation of upcoming cardiac clearances. As Lonnie mentioned, we submitted a 510k to the FDA after the completion of our Mtral Valve study. The results were excellent and the company expects to obtain clearance for this cardiac procedure before the end of this year. Cases for our AST repair trail are progressing well and nearing completion. We expect to receive FDA clearance for this indication early next year. Cases are also ongoing for our cavage trial and we target cavage clearance by the end of 2003. As these clearances approach, we see more cardiac centers initiating the formation of minimally invasive cardiac programs at their institutions. That completes my summary and I will pass the time over to Aleks Cukic.
謝謝你,Susan。我很高興報告,本季我們在三個主要外科市場——泌尿科、一般外科以及心胸外科——各自都取得了顯著的臨床進展。就泌尿科市場而言,我們所稱的達文西前列腺切除術(DVP)本季再度表現出色,手術量持續成長,執行該手術的醫療機構數量也持續增加。隨著病例數增加,支持DVP明確效益的臨床證據也日益累積。在《Journal of Urology》九月號中,刊登了一篇比較DVP與腹腔鏡前列腺切除術臨床結果的文章。雖然相較於傳統開腹技術的優勢顯而易見,但該研究將亨利福特醫院(Henryford Hospital)Mani Menon醫師所執行的前40例(包含學習曲線)與全球最有經驗的腹腔鏡前列腺手術醫師——Dr. Givelensian與Dr. Bertrand Genive——合計超過600例的結果進行比較。使用達文西的平均手術時間為274分鐘,而腹腔鏡手術為258分鐘。不過請注意,Menon醫師目前在學習曲線上已更為成熟,例行手術時間約為120分鐘,較最有經驗的腹腔鏡醫師快2小時。該研究也探討了病人受益。DVP的平均失血量僅256 cc,相較之下LRP為391 cc。此外,DVP的癌症切除更為完整,手術切緣陽性率為17.5%,而LRP為25%。最後,80%的達文西病人在手術後24小時內出院,相較之下使用腹腔鏡技術者為65%。病人於24小時出院,代表相較於開腹手術住院恢復期可縮短2.5至3天。除了為達文西系統提供極佳的手術量基礎外,DVP也為許多可透過機器人技術改善的其他泌尿科手術打開了大門。我們在多種泌尿科手術上也正經歷成長,例如腎盂成形術(pyeloplasty)與部分腎切除術(partial nephrectomy)。在《Urology》九月號刊登的一篇文章中,羅徹斯特男性診所(Male Clinic Rochester)報告指出,與傳統腹腔鏡技術相比,使用達文西進行腎盂成形術可將其院內平均手術時間由214分鐘縮短至139分鐘。此外,克里夫蘭診所(Cleveland Clinic)的一組整形外科與泌尿科醫師完成了全球首例合併雙側腓腸神經(sural nerve)移植的DVP。此手術包含自腿部取下一段皮神經,並用以恢復在前列腺切除過程中被切除之神經束的連續性。預期神經移植的使用可在前列腺切除後改善性功能(potency)。最後,在紐約大學醫學中心(New York University Medical Center),外科醫師已在部分腎切除術中累積使用達文西的經驗。部分腎切除術適用於切除小於4公分的腎臟腫瘤。此手術屬於重建性手術,可用來替代腎臟移植。在器官日益短缺的情況下,修復而非更換病變腎臟的能力將極具價值。在心臟領域,我們在微創冠狀動脈繞道手術方面已取得進展動能。多家歐洲機構已例行以達文西作為主要手術工具,執行不停跳心臟繞道手術。近期,Dr. Gearhart van Engraniger在一場歐洲心臟外科醫師會議上,進行了一場閉胸內視鏡不停跳心臟繞道手術的現場直播,且在不到2小時內完成。在美國國內,隨著即將到來的心臟適應症核准,心臟領域的動能也正在累積。如Lonnie先前提到的,我們在完成二尖瓣(Mtral Valve)研究後,已向FDA提交510k申請。結果非常優異,公司預期可在今年年底前取得該心臟手術的核准。我們的AST修補試驗(AST repair trail)病例進展順利,接近完成。我們預期可在明年年初取得FDA對此適應症的核准。我們的冠狀動脈繞道(cavage)試驗病例也仍在進行中,目標是在2003年底前取得cavage核准。隨著這些核准時點接近,我們看到更多心臟中心開始在其機構內推動建立微創心臟計畫。以上是我的摘要,接下來我把時間交給Aleks Cukic。
ALEKS CUKIC - Intuitive Surgical
ALEKS CUKIC - Intuitive Surgical
Thank you Fred. As was previously mentioned, we shipped 14 da Vinci surgical systems during the third quarter. We had another strong quarter in the US with 13 of the 14 units going to US customers. The other system was sold in Europe. We continue to see higher percentages of systems shipped to community hospitals versus academic institutions. This quarter 12 of the 14 systems shipped went to community hospitals. This is our highest quarterly concentration into this segment and helps confirm the value that da Vinci surgical system provides to mainstream hospitals. During the quarter, we made 2 additional sales of second systems into existing accounts. We sold a second system into Memorial Herman Hospital in Houston, Texas as well as a second system to Santonio Medical Center in Nashville, Tennessee. That now makes a total of 9 sites with 2 da Vinci surgical systems. The second system at Santonio Medical Center is significant in that HCA has established Santonio as a da Vinci training center for all HCA hospitals. This investment demonstrates HCA's commitment to robotics and to Intuitive Surgical. Intuitive Surgical recently took part in a number of key trade show events. The European Association of Cardio thoracic Surgery held in Monaco, the Society of Laparo-Endoscopic Surgeons' Conference in New Orleans, and American College of Surgeons held in San Francisco. The highlight of each of these meetings was a live surgery broadcast. At EX, we presented a live telecast of a totally endoscopic beating heart bypass procedure using the da Vinci. At SLS, it was a gastric banding procedure and at ACS, we broadcast a gastric bypass surgery procedure into the Ethicon Endo-Surgery tool. As we had 10 more of these shows we are finding that participants placed more and more focus on surgical and clinical capability of the da Vinci to perform specific procedures. Now that surgeons have gotten past the technology "wow" phase, they become very interested in observing other surgeons performing da Vinci procedures as well as understanding the steps required to build a multidisciplinary robotics program within their own facilities. With a 132 da Vincis placed throughout the world, numerous preceptors and proctors are in place along with Intuitive Surgical's established clinical training pathways, we find ourselves uniquely positioned to meet all of the market's clinical needs. As minimally invasive robotic surgery climbs the adoption curve, we find customers less focused on technical theories and more focused on evidence-based medicine. We not only encourage this shift but also embrace it. At this time, I will pass the time over to David Shaw who will discuss the legal developments of the quarter.
謝謝你,Fred。如先前所提到的,我們在第三季出貨了14套達文西手術系統。我們在美國市場本季表現依然強勁,14套中有13套出貨給美國客戶。另外1套售往歐洲。我們持續看到出貨至社區醫院(community hospitals)的比例高於學術機構。本季出貨的14套中有12套交付社區醫院。這是我們單季在此細分市場的最高集中度,也有助於印證達文西手術系統為主流醫院所帶來的價值。本季我們在既有客戶中另外完成了2筆第二套系統的銷售。我們在德州休士頓的Memorial Herman Hospital售出第二套系統,並在田納西州納什維爾的Santonio Medical Center也售出第二套系統。目前共有9個據點配置了2套達文西手術系統。Santonio Medical Center的第二套系統具有重要意義,因為HCA已將Santonio設立為所有HCA醫院的達文西訓練中心。這項投資展現了HCA對機器人技術以及對Intuitive Surgical的承諾。Intuitive Surgical近期參與了多場重要的展會活動。包括在摩納哥舉辦的歐洲心胸外科協會(European Association of Cardio thoracic Surgery)、在紐奧良舉辦的腹腔鏡—內視鏡外科醫師學會(Society of Laparo-Endoscopic Surgeons)年會,以及在舊金山舉辦的美國外科醫師學會(American College of Surgeons)。這些會議的亮點都是現場手術直播。在EX上,我們以達文西進行全內視鏡不停跳心臟繞道手術的現場轉播。在SLS上,則是胃束帶(gastric banding)手術;在ACS上,我們將胃繞道手術的直播轉播到Ethicon Endo-Surgery工具中。隨著我們又多進行了10場此類展示,我們發現與會者愈來愈聚焦於達文西在執行特定手術時的外科與臨床能力。如今外科醫師已經走過對技術「驚豔」的階段,他們更有興趣觀摩其他外科醫師執行達文西手術,並了解在其自身機構內建立跨專科機器人計畫所需的步驟。目前全球已部署132套達文西系統,並有眾多指導醫師(preceptors)與督導醫師(proctors)到位,加上Intuitive Surgical既有的臨床訓練路徑,使我們具備獨特優勢,能滿足市場所有臨床需求。隨著微創機器人手術沿著採用曲線攀升,我們發現客戶對技術理論的關注降低,轉而更重視循證醫學(evidence-based medicine)。我們不僅鼓勵這樣的轉變,也樂於擁抱它。接下來,我把時間交給David Shaw,他將說明本季的法律進展。
DAVID M. SHAW - Intuitive Surgical
DAVID M. SHAW - Intuitive Surgical
Thanks Alecks. This past quarter we continued to invest in our joint Delaware litigation with IBM against Computer Motion on our patent covering voice-controlled surgical robots. As was previously announced by Press Release], the jury faced with the Delaware trial came to a favorable conclusion in August. After 6 days of evidence and a day of deliberations, the Delaware jury concluded that Computer Motion failed to invalidate any claim of our patent. Since Computer Motion had already admitted its AESOP and ZEUS products infringe our patent, the jury awarded $4.4 million in damages. Needless to say that we are pleased with how this is case is progressing. The case is now on the post trial phase. Both sides have agreed Computer Motion's equitable defensive prosecution latches and await the court's decision, which may not issue for several more months. More arguement the issue will occur next week. In the ongoing litigation against Computer Motion in California, there is really not much to add to what we have preciously said. Our first four motions for summary judgment of non-infringement remain pending and briefing is now concluded on 2004. Oral argument is concluded on two of them. Oral argument on the other two will occur in November. We continue to expect decisions on these four motions to start issuing sometime in the next several months and we also continue to anticipate filing further motions for summary judgment after the court has decided those already are on file. Other than that, discovery continues. Finally, we continue to add to our own portfolio of patents. This past month, for example, we closed another exclusive license in computerized surgery through a third-party patent on a variety of articulating surgical instruments. We believe that patent will be useful in the future to protect our inventive strides. And that completes the legal summary. Now I will pass the time back to Lonnie.
謝謝你,Alecks。在過去這一季,我們持續投入與 IBM 在德拉瓦州針對 Computer Motion 共同進行的訴訟,該案涉及我們涵蓋語音控制手術機器人的專利。如先前新聞稿所宣布,德拉瓦州審判的陪審團於八月作出對我們有利的結論。在為期 6 天的舉證與 1 天的評議後,德拉瓦州陪審團認定 Computer Motion 未能使我們專利的任何權利項無效。由於 Computer Motion 先前已承認其 AESOP 與 ZEUS 產品侵害我們的專利,陪審團裁定 440 萬美元的損害賠償。不用說,我們對本案的進展感到滿意。本案目前進入審後階段。雙方已就 Computer Motion 所主張的衡平法抗辯(equitable defensive prosecution laches)達成一致,並等待法院裁定;該裁定可能還要再過數月才會出爐。關於該議題的進一步辯論將於下週進行。至於在加州對 Computer Motion 的持續訴訟,基本上沒有太多內容可補充,與我們先前所述相同。我們提出的前四項不侵權簡易判決動議仍在待裁中,相關書狀程序現已於 2004 年結束。其中兩項已完成口頭辯論。另外兩項的口頭辯論將於十一月進行。我們仍預期法院將在未來數月內陸續就這四項動議作出裁定;同時,我們也仍預期在法院就目前已提出的動議作出裁定後,將再提出進一步的簡易判決動議。除此之外,證據開示仍在進行。最後,我們也持續擴充自身的專利組合。例如在上個月,我們透過第三方專利,就電腦輔助手術領域中多種可關節式手術器械,完成了另一項獨家授權。我們相信該專利未來將有助於保護我們的創新成果。以上為法務摘要。現在我把時間交回給 Lonnie。
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
That concludes our presentation. We will now open the floor to any questions you might have.
我們的簡報到此結束。接下來我們將開放現場,回答各位可能有的問題。
Operator
Operator
Thank you participants. If you would like to ask a question, please signal by pressing *1 on your phone keypads. If your question has been answered and you wish to withdraw, then you would press *2. Once again, that is *1 to ask a question and *2 to cancel. In some cases you may have to lift your hand receiver prior to pressing *1 if you are using a speaker equipment. One moment while question register please. And our first question comes from Ms. Sitar Mato with Bear Sterns.
謝謝各位與會者。若您想提問,請在電話鍵盤上按 *1 示意。若您的問題已獲回答且希望取消排隊,請按 *2。再重複一次,按 *1 提問,按 *2 取消。在某些情況下,若您使用擴音設備,可能需要先拿起話筒再按 *1。請稍候,我們正在登記問題。我們的第一個問題來自 Bear Sterns 的 Ms. Sitar Mato。
SITAR MATO - Analyst
SITAR MATO - Analyst
Good afternoon. I guess, although, from the sound of my voice I am a female. Couple of questions. First on this non-recurring items, the unauthorized purchase of these administrative supplies. Can you give any further clarity as to what happened and I understand that you probably do not feel compelled to say a lot, but can you discuss may be when you expect to get a refund or when we could see that money back from the losses? That is my first question.
午安。我想,雖然從我的聲音聽得出來我是女性。我有幾個問題。第一個是關於這些一次性項目,也就是未經授權購買行政用品一事。你們能否更清楚說明發生了什麼?我理解你們可能不便多談,但能否談談你們預期何時能拿到退款,或我們何時可能看到這筆損失的資金回流?這是我的第一個問題。
SUSAN K. BARNES - Intuitive Surgical
SUSAN K. BARNES - Intuitive Surgical
This is Susan. One thing that we want to make clear is that we are clear that the $936,000 is a complete amount, we have reconciled our accounts to make sure that and our auditors have reviewed our reconciliation processes. The details on any further on who, what, when, and how we are really investigating using the law enforcement to investigate and get us the details on that. Part of that is negotiation with the vendors as well as claims on our insurance. We do not feel that those are coming anytime soon and that is just as far as we can go on where we see this coming.
我是 Susan。我們想先釐清的一點是:我們確認 936,000 美元是完整金額;我們已對帳以確保無誤,且我們的稽核人員也已審閱我們的對帳流程。至於更進一步的細節——誰、什麼、何時、以及如何發生——我們正透過執法機關進行調查,以取得相關細節。其中一部分也包含與供應商的協商,以及向我們的保險提出理賠。我們不認為這些會在短期內有結果;就我們目前能掌握的情況而言,也只能說到這裡。
SITAR MATO - Analyst
SITAR MATO - Analyst
Okay.
好的。
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
But we do have...we have clearly identified the person and exactly what happened. But obviously with the kind of process of law moves slower than we would like.
不過我們確實已經……我們已清楚辨識出相關人員,也確定究竟發生了什麼事。但顯然,法律程序的進展比我們希望的要慢。
SITAR MATO - Analyst
SITAR MATO - Analyst
But you do not expect any material change from this $930,000 number?
但你們不預期這個 930,000 美元的數字會有任何重大變動嗎?
SUSAN K. BARNES - Intuitive Surgical
SUSAN K. BARNES - Intuitive Surgical
That is the complete amount. It has all been booked. And we have as we said tightened our procedures, so this kind of event cannot happen again.
那就是完整金額。也都已入帳。而且如我們所說,我們已強化流程,因此這類事件不會再發生。
SITAR MATO - Analyst
SITAR MATO - Analyst
Okay.
好的。
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
And that values all the material at 0.
而且該金額已將所有物料價值計為 0。
SITAR MATO - Analyst
SITAR MATO - Analyst
Okay. Second question is regarding litigation but also have you had any ongoing discussions with Computer Motion with regard to settling the Delaware suit or the California suit for this matter? Have there been any conversations between you guys and Computer Motion that you can update us on?
好的。第二個問題是關於訴訟:你們是否曾與 Computer Motion 就和解德拉瓦州案件或加州案件進行任何持續性的討論?你們與 Computer Motion 之間是否有任何對話可以更新給我們?
DAVID M. SHAW - Intuitive Surgical
DAVID M. SHAW - Intuitive Surgical
We have nothing new to share with you at this time.
目前我們沒有新的資訊可以與各位分享。
SITAR MATO - Analyst
SITAR MATO - Analyst
Okay. And then may last question is regarding international - this year you placed 5 systems in Europe. Is there something, I know it is a very price-sensitive barrier, but is there something else going on there it seems surprisingly low relative to what you guys did last year in Europe?
好的。那我最後一個問題是關於國際市場——今年你們在歐洲安裝了 5 套系統。是否有其他因素?我知道那裡對價格非常敏感是一個門檻,但相較於你們去年在歐洲的表現,這個數字似乎意外地低;那邊是不是還有其他狀況?
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
Well, while we are very pleased with the sales growth and the momentum in the US, we have not met our internal sales goals in Europe and we are not comfortable with the current visibility we have on the timing of several significant projects in Europe. So, therefore we have become a little more conservative in our projections, but as I mentioned earlier we have brought on board Esco Viscari as head of our European sales and marketing effort and he will bring some significant leadership to unremarkable sales and marketing organization over there. It is more price-sensitive but we also believe that we have not executed as well as we should have.
嗯,雖然我們對美國市場的銷售成長與動能感到非常滿意,但我們在歐洲並未達成內部的銷售目標,而且對於歐洲數個重大專案的時程,我們目前掌握的能見度不足,讓我們不太放心。因此,我們在預測上變得稍微保守一些;不過如我先前提到的,我們已延攬 Esco Viscari 擔任歐洲銷售與行銷工作的負責人,他將為那邊表現平平的銷售與行銷組織帶來重要的領導力。那裡確實更具價格敏感性,但我們也認為我們的執行力沒有做到應有的水準。
SITAR MATO - Analyst
SITAR MATO - Analyst
Okay, great. Thank you very much.
好的,很好。非常感謝。
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
Thank you.
謝謝。
Operator
Operator
Thank you. My apologies Ms. Mato. And our next question comes from Mr. Kevin Dede of Wells Fargo Securities.
謝謝。Mato 女士,抱歉。下一個問題來自 Wells Fargo Securities 的 Kevin Dede 先生。
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
Hi, Dede.
嗨,Dede。
KEVIN DEDE - Analyst
KEVIN DEDE - Analyst
Good afternoon. How are you doing?
午安。你最近如何?
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
Great.
很好。
KEVIN DEDE - Analyst
KEVIN DEDE - Analyst
Glad to see you are getting this call done before the Giants came tonight. I got a couple of questions if I may. Could you comment a bit more specifically on, given the strength in the US business, what you anticipate going forward as relates to academic placements versus community centers we have normally discussed this on the calls before and I know there are some comments as to why should that going forward clearly had a significant community hospital interest in recent quarters accounting for the majority of US placements. What do you expect looking ahead in the next couple of quarters in that regard?
很高興看到你們在今晚巨人隊比賽開始前就把這通電話開完。如果可以的話我有幾個問題。鑑於美國業務的強勁表現,你能否更具體評論一下你們對未來的預期:就學術機構的裝機(academic placements)相對於我們過去在電話會議中常討論的社區中心(community centers)而言,接下來你們怎麼看?我知道先前也有一些評論,說明為何未來會如此;而且很明顯,近幾季社區醫院的興趣相當高,佔了美國裝機的大多數。就這一點而言,你們對未來一兩季的展望是什麼?
ALEKS CUKIC - Intuitive Surgical
ALEKS CUKIC - Intuitive Surgical
This is Alecks Cukic. With respect to community versus academic-based facilities, I think an important note to keep in mind is there are only approximately 150 academic based medical schools with hospitals in the US and with 88 of our systems already placed within the US, we have a very good penetration. Certainly in the top tier hospitals, the medical universities, as well as many of the mid-level medical schools. We have a very high penetration there. I think it is also important to note that there are approximately 1500 cardiac programs within the US and over 4000 hospitals within US. So, the percentage of academic versus community is certainly going to weigh toward the community side which is by far the bigger of the 2 markets and the one that we think is the one we have to penetrate deeper.
我是 Alecks Cukic。就社區型醫療機構與學術型醫療機構而言,我認為需要記住的一個重點是,美國只有大約 150 所附設醫院的學術型醫學院;而我們的系統已有 88 套部署在美國,因此我們的滲透率非常高。當然,在頂尖醫院、醫學大學,以及許多中等規模的醫學院也是如此。我們在那裡的滲透率非常高。同時也要注意,美國約有 1500 個心臟科計畫,以及超過 4000 家醫院。因此,學術型相對於社區型的占比,必然會更偏向社區端;社區端是兩個市場中規模遠大的一方,也是我們認為必須更深入滲透的市場。
KEVIN DEDE - Analyst
KEVIN DEDE - Analyst
Following up on your comment on the cardiac placement opportunities in various centers, obviously you got the key for expectation on mitral valve. Looking ahead however, the broader cardiac approval will likely drive utilization significantly higher for the systems, so I realize there remains an uncertain timeline here on that, but can you describe the dynamics as well as it relates to the purchase of the system ahead of that broad approval and my impression has been that you have had some major cardiac figures driving to some degree system purchases already ahead of the cardiovascular approvals. Can you just comment on that side of things please?
延續您對於在各類中心的心臟科裝機機會的評論,顯然您已掌握對二尖瓣的預期。不過展望未來,更廣泛的心臟科核准很可能會顯著推升系統的使用量;我理解在這方面仍有不確定的時間表,但您能否說明相關動態,尤其是就廣泛核准之前先行購買系統的情況而言?我的印象是,已有一些重要的心臟科權威人士在某種程度上推動了在心血管核准之前就先行購買系統。能否就這一面向請您評論一下?
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
Sure, I will be glad to. With respect to the growth of procedures that may fall under cardiac in many of our minds but are certainly thoracic procedures like IMA takedown which we have been able to perform for several years now under our thoracic approval. Those are going to be steps that are going to be absolutely imperative to ultimate cavage procedures which we hope to receive approval in 2003. So, many of the hospitals and many of the placements are already getting inline with that part of the procedure in addition to the mitral valve, which will be approved this quarter. One thing to keep in mind aside from cardiac is we are approaching our sales with a multidisciplinary approach. In other words, urologic, general, and cardiac. Although cardiac is a key driver, our most successful hospitals are the one that are taking full advantage of our approvals and taking it across all surgical disciplines that are approved, therefore lowering the cost per department of the investment. So, we see that continuing and only picking up in the future.
當然,我很樂意。就許多人心目中可能歸類為心臟科、但實際上屬於胸腔手術的程序而言,例如 IMA(內乳動脈)游離(takedown),我們在胸腔適應症核准下已能執行好幾年。這些將是邁向最終 cavage 手術(我們希望在 2003 年取得核准)絕對不可或缺的步驟。因此,許多醫院與許多裝機點,除了二尖瓣(將於本季獲核准)之外,也已在為該部分手術流程做準備並與之接軌。另外除了心臟科之外,有一點要記住:我們正以多學科方式推進銷售。換言之,泌尿科、一般外科與心臟科。雖然心臟科是關鍵驅動因素,但我們最成功的醫院,是那些充分利用我們已獲核准的適應症,並將其擴展到所有已核准的外科領域,從而降低各科室分攤的投資成本。因此,我們預期這種趨勢會延續,且未來只會更加明顯。
KEVIN DEDE - Analyst
KEVIN DEDE - Analyst
Okay. And just one last question briefly. Can you comment as relates to the visibility you continue to get by having a da Vinci in J&J's training facility? What specifically are you getting out of that in terms of leads? Is it possible to track looking ahead and any other benefits from your relationship from J&J and for that matter do you anticipate a broader relationship with J&J looking ahead?
好的。最後再簡短問一個問題。您能否評論一下,將一套 da Vinci 放在 J&J 的訓練中心,對您持續帶來的能見度有何幫助?就線索(leads)而言,您具體獲得了什麼?未來是否可能追蹤其效果?以及您與 J&J 的關係還有其他好處嗎?此外,就此而言,您是否預期未來與 J&J 會有更廣泛的合作關係?
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
First part of that question - if you look back to the original press release and the original comments that we have made on the relationship with J&J specifically at the Carnendo relationship. It was really framed up on three legs. The first leg was professional education and co-training, the second was with respect to co-marketing, and the third is co-product development. So, if you take a look at where we are with respect to the professional training and education, I speak for Ethicon for this as well, are very satisfied with the number of people that have passed through the Ethicon Surgical Institute as well as the people that have passed out that have actually taken da Vinci for test drive and done clinical lab work with da Vinci as well as the co-marketing that Lonnie had mentioned earlier that we are doing and things like ACS with live procedures being broadcast into the boot and those things are going very well. We are taking a look at a number of different co-development opportunities as we speak so as it sits now I would say that we are very happy with that relationship and look to prolong our relationship with them in the future.
關於問題的第一部分——如果回顧最初的新聞稿,以及我們先前對與 J&J 的關係(特別是 Carnendo 的合作關係)所做的原始評論。當時其實是以三個支柱來架構。第一個支柱是專業教育與共同訓練,第二個是共同市場推廣(co-marketing),第三個是共同產品開發。因此,若看我們在專業訓練與教育方面的進展,我也代表 Ethicon 說明:我們對於通過 Ethicon Surgical Institute 的人數,以及那些實際對 da Vinci 進行「試駕」、並使用 da Vinci 進行臨床實驗室操作的人數,都非常滿意;此外,還有 Lonnie 先前提到的共同市場推廣,例如 ACS 等活動,將即時手術轉播到展位(booth)等,這些進展都非常順利。我們目前也正在評估多項共同開發機會;因此就現況而言,我會說我們對這段合作關係非常滿意,並希望未來能延續與他們的合作。
KEVIN DEDE - Analyst
KEVIN DEDE - Analyst
Thanks very much.
非常感謝。
Operator
Operator
Thank you. Our next question comes from Mr. Neil Gagnan of Gagnan Securities.
謝謝。下一個問題來自 Gagnan Securities 的 Neil Gagnan 先生。
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
Hi, Neil.
嗨,Neil。
NEIL GAGNAN - Analyst
NEIL GAGNAN - Analyst
Hi, folks. Can you give us some background on what is going on with usage per machine?
嗨,各位。你們能否提供一些背景,說明每台機器的使用量目前的情況?
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
The usage is building. I think we have not given specific numbers by system and we are still not willing to do that but we feel very good about the way it significant progressing. We had a record quarter in terms of number of procedures and it continues to ramp on the number of procedures per system and we feel like we are making excellent progress there. It continues to be one of our major areas of emphasis in terms of driving this as Alecks mentioned across multiple procedures and multiple disciplines.
使用量正在提升。我想我們尚未按系統披露具體數字,而且目前仍不打算這麼做,但我們對其顯著進展的態勢感到非常樂觀。就手術例數而言,我們本季創下紀錄;每套系統的手術量也持續爬升,我們覺得在這方面進展非常出色。這仍是我們重點投入的主要領域之一,正如 Alecks 提到的,我們正跨多種手術與多個專科來推動使用量。
NEIL GAGNAN - Analyst
NEIL GAGNAN - Analyst
Okay. Let me ask a couple of financial type questions. The SG&A you built in the third quarter and you had talked about that but it was built in the second quarter and as I remember that was legal also. And there has not been that much headcount growth this year. So I am guessing that your total SG&A is something like $2.5 to 3 million over what it should be leaving your current operations this quarter.
好的。我想問幾個偏財務類的問題。你們第三季的 SG&A 增加了,你們也談過這點;但第二季也增加了,而我記得那部分也包含法律費用。而且今年人員編制(headcount)並沒有增加太多。所以我猜,你們本季的總 SG&A 大概比在目前營運狀態下應有的水準高出約 250 萬到 300 萬美元。
SUSAN K. BARNES - Intuitive Surgical
SUSAN K. BARNES - Intuitive Surgical
We do not disclose that.
我們不披露那個。
NEIL GAGNAN - Analyst
NEIL GAGNAN - Analyst
Wait a minute. Susan, lets back it up here. Your headcount went up next to nothing in the quarter?
等一下。Susan,我們先退一步。你們本季的人員編制幾乎沒有增加?
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
It went up 2 million.
增加了 200 萬。
NEIL GAGNAN - Analyst
NEIL GAGNAN - Analyst
Okay. So, you cannot spend it otherwise.
好的。所以,你們不可能把錢花在別的地方。
SUSAN K. BARNES - Intuitive Surgical
SUSAN K. BARNES - Intuitive Surgical
That is fair.
這樣說也合理。
NEIL GAGNAN - Analyst
NEIL GAGNAN - Analyst
That is fair. And your SG&A also went up a million dollars in Q2 without much headcount growth.
這樣說也合理。而你們第二季的 SG&A 也增加了 100 萬美元,但人員編制並沒有明顯成長。
BENJAMIN M. GONG - Intuitive Surgical
BENJAMIN M. GONG - Intuitive Surgical
I think there is a little bit of delay effect on the expenses versus the headcount growth. A lot of times you can add people in prior quarter and then you get the full impact of the expenses in the following quarter.
我認為費用相對於人員編制成長之間,會有一些滯後效應。很多時候你可能在前一季先增聘人員,但費用的完整影響會在下一季才完全反映出來。
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
What is important for us though, folks, is to have an idea of what your true operating costs are.
不過對我們來說,各位,重要的是要了解你們真正的營運成本是多少。
BENJAMIN M. GONG - Intuitive Surgical
BENJAMIN M. GONG - Intuitive Surgical
And I would like to add some may be in this way. Other than the two sort of non-recurring items that happened in the third quarter, our expenses would've been inline in the SG&A area from where we had planned and also where I believe our analysts had it planned, which is probably closer to an order of $14 million in total operating expenses versus the $15.6 million that we reported.
我也想補充一點,或許可以這樣說:除了第三季發生的兩項較偏一次性的項目之外,我們的費用本來會在 SG&A 方面與我們的規劃一致,也與我認為分析師的規劃一致;也就是總營運費用大概接近 1400 萬美元,而不是我們所報告的 1560 萬美元。
SUSAN K. BARNES - Intuitive Surgical
SUSAN K. BARNES - Intuitive Surgical
The other thing that I want you to understand is that the legal and litigation expenses are not something that we see as a one-time quarter head for, but these are built into the practice of our business and are defense of our intellectual property and that is why we do not want to leave you too far straight on one-time quarterly hits.
我希望你們理解的另一件事是,法律與訴訟費用並不是我們視為一次性、只會在某一季出現的項目;相反地,這些費用已內建於我們的營運實務之中,用於捍衛我們的智慧財產權,因此我們不希望你們把它視為單一季度的一次性衝擊。
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
On the other hand, they are higher than we would certainly expect on an ongoing run rate because of the litigation and that is absolutely true. Neil, one of the things that we are doing here is investment right now, we are fully invested and fully staffed pretty much at our offices here in Sunnyvale and our factory and in our Engineering and R&D and all sort of things. So, that is going to stay pretty flat. What we are going to is we will continue to build. Our investment will be in the field both in field sales, clinical support and service because that is where the growth is going to be and of course the goal here is to hold the fixed costs constant except for those costs in the field and build sales and crossover into profitability and clearly this misallocation of funds, do not know how to describe it, I would probably describe it more strong.
另一方面,因為訴訟的關係,這些費用確實高於我們對持續性常態支出水準(run rate)的預期,這點完全正確。Neil,我們目前正在做的一件事是投資;我們已經幾乎在Sunnyvale的辦公室、工廠,以及工程與研發等各方面都達到全面投資、全面編制。因此,這部分將會維持相當平穩。我們接下來要做的是持續建置。我們的投資將會放在前線,包括外勤銷售、臨床支援與服務,因為成長將來自那裡;當然,我們的目標是在前線相關成本之外,將固定成本維持不變,並提升銷售、跨越到獲利狀態。至於這種資金錯置——不知道該怎麼形容——我可能會用更強烈的措辭來描述。
NEIL GAGNAN - Analyst
NEIL GAGNAN - Analyst
Your revenues were not too bad, so that is not a big deal.
你們的營收其實不算太差,所以那不是什麼大問題。
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
Yeah, anyway. That was disappointing, very disappointing.
是啊,總之。那很令人失望,非常令人失望。
NEIL GAGNAN - Analyst
NEIL GAGNAN - Analyst
Lets talk about gross margins. As you ramp up form here and look at your product mix and revenue mix and as you add another dollar of revenue, what should be the gross margin effect or what is the incremental margin?
我們來談談毛利率。當你們從這裡開始放量,並觀察你們的產品組合與營收組合時,當你們每增加一美元營收,毛利率的影響會是什麼?或者說,增量毛利是多少?
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
A dollar of revenue?
一美元的營收?
NEIL GAGNAN - Analyst
NEIL GAGNAN - Analyst
Yep.
對。
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
It is almost 60%, 50 some percent, high 50s.
大概接近60%,五十幾個百分點,高五十幾。
NEIL GAGNAN - Analyst
NEIL GAGNAN - Analyst
That is fine. Thank you.
很好。謝謝你。
Operator
Operator
Thank you once again participant. If you would like to ask a question, please signal by pressing *1 on you phone keypads. And our next question comes from Mr. Mark Smiley of Cydler & Co.
再次感謝各位與會者。若您想提問,請在電話鍵盤上按 *1 示意。下一個問題來自 Cydler & Co. 的 Mark Smiley 先生。
MARK SMILEY - Analyst
MARK SMILEY - Analyst
Can you guys hear me okay?
你們聽得到我嗎?
SUSAN K. BARNES - Intuitive Surgical
SUSAN K. BARNES - Intuitive Surgical
Yes.
聽得到。
MARK SMILEY - Analyst
MARK SMILEY - Analyst
The question I had was what kind of incremental revenue can expect from introducing a fourth arm back to the existing placed units?
我想問的是,將第四支手臂回裝到既有已安裝的設備上,預期可以帶來多少增量營收?
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
I am not sure we are ready to forecast that at this point in time. We have introduced that. We have not launched it yet. We will launch it early next year and it is still in clinicals right now. So, we are not ready to incorporate that into our business projections.
我不確定我們目前是否已準備好在此時做出預測。我們已經導入那項產品。但我們尚未正式上市。我們會在明年初推出,而目前仍在臨床階段。因此,我們還沒準備好把它納入我們的業務預測。
MARK SMILEY - Analyst
MARK SMILEY - Analyst
Okay, thanks.
好的,謝謝。
Operator
Operator
Thank you. And once again participants, if you would like to ask a question please signal by pressing *1 on your phone keypads. And our next question comes from Mr. John Massey of Bear Sterns.
謝謝。再次提醒各位與會者,若您想提問,請在電話鍵盤上按 *1 示意。下一個問題來自 Bear Sterns 的 John Massey 先生。
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
Hi, John.
嗨,John。
JOHN MASSEY
JOHN MASSEY
Before I ask a question, obviously we have strip out the unauthorized purchase of supplies and we come to 14.7 in operating expenses. Should we expect from that number fourth quarter to be down?
在我提問之前,顯然我們已把未經授權的耗材採購剔除,營業費用就會是14.7。我們是否可以預期第四季會比這個數字更低?
SUSAN K. BARNES - Intuitive Surgical
SUSAN K. BARNES - Intuitive Surgical
I think what we said John was that again we are continuing to invest the fields that you have to take the number down from the total number of the 15.6.
John,我想我們說的是:同樣地,我們會持續投資前線,因此你需要從總數15.6中把那部分調整下來看。
JOHN MASSEY
JOHN MASSEY
Okay. Can you tell us though what we should expect from litigation costs going forward in the fourth quarter?
好的。不過你能否告訴我們,第四季往後訴訟成本大概會是什麼水準?
SUSAN K. BARNES - Intuitive Surgical
SUSAN K. BARNES - Intuitive Surgical
We believe that exposing litigation cost is still proprietary and that while they will be there, they will not be as heavy as the third quarter with the trial.
我們認為揭露訴訟成本仍屬於專有資訊;雖然這些成本仍會存在,但不會像第三季因為開庭審理而那麼沉重。
JOHN MASSEY
JOHN MASSEY
Okay. That is what I wanted. Thanks.
好的。這就是我想知道的。謝謝。
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
We will take one more question and then close.
我們再接一個問題,然後就結束。
Operator
Operator
Thank you. Our next question comes from Raymond Myers of Boston Partners.
謝謝。下一個問題來自 Boston Partners 的 Raymond Myers。
RAYMOND MYERS - Analyst
RAYMOND MYERS - Analyst
Yes thank you. If I could may be just two quick ones. One is how is pricing holding up? And the other one is your guidance for the full year with 18-22 systems in the fourth quarter is the guidance for the full year coming down a little bit from what you gave in the second quarter?
是的,謝謝。如果可以的話,我可能有兩個簡短問題。第一個是,定價表現如何?第二個是,你們對全年指引中,第四季18到22套系統的指引,是否比你們在第二季給出的全年指引略為下修?
SUSAN K. BARNES - Intuitive Surgical
SUSAN K. BARNES - Intuitive Surgical
Pricing has come up every year since we introduced the da Vinci in the US market and we continue to see that pattern going forward.
自從我們在美國市場推出 da Vinci 以來,價格每年都有上調,我們也持續看到這種趨勢延續到未來。
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
And as I mentioned earlier, while we are very comfortable with the sales growth momentum in the US, because Europe has not met its sales goals and we do not feel real comfortable with the current visibility on the timing of some of several European projects, we have become a little more conservative in our projections for the fourth quarter.
如我先前提到的,雖然我們對美國的銷售成長動能非常有信心,但由於歐洲未達成其銷售目標,而且我們對若干歐洲專案時程的能見度目前不太有把握,因此我們在第四季的預測上變得稍微保守一些。
BENJAMIN M. GONG - Intuitive Surgical
BENJAMIN M. GONG - Intuitive Surgical
Ray, in response to your question on the full year, our previous guidance had been 40-50% revenue growth over the prior year and that is still inline with what our guidance is now.
Ray,回應你關於全年的問題,我們先前的指引是相較前一年營收成長40%到50%,而這仍與我們目前的指引一致。
RAYMOND MYERS - Analyst
RAYMOND MYERS - Analyst
Okay, good luck.
好的,祝順利。
LONNIE M. SMITH - Intuitive Surgical
LONNIE M. SMITH - Intuitive Surgical
That concludes our presentation and the Q&A. What I would like to do is summarize the highlights for the third quarter the third quarter once more. We shipped 14 da Vinci surgical systems, we achieved $17.1 million in revenue, up 57% from prior year, we grew recurring revenue to a record $3.9 million, up 135% from prior year, and we ended the quarter with $45.8 million in cash. We won a $4.4 million jury verdict versus Computer Motion, but as David said the latches' decision is still pending. We released two new energy-based products and we submitted our mitral valve repair 510k to the FDA and expect clearance in the fourth quarter. That concludes today's call and we thank you all for your participation.
以上結束我們的簡報與問答。我想再一次總結第三季的重點。我們出貨了14套 da Vinci 手術系統,達成1,710萬美元營收,較去年同期成長57%;我們將經常性收入提升至創紀錄的390萬美元,較去年同期成長135%;季度結束時現金為4,580萬美元。我們在對 Computer Motion 的訴訟中獲得440萬美元的陪審團裁決,但如 David 所說,關於 latches 的裁定仍在等待中。我們發布了兩項新的能量型產品,並向 FDA 提交了二尖瓣修復的 510k,預期在第四季取得核准。今天的電話會議到此結束,感謝各位的參與。